Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431422 | 0.88 | HSD17B10 (0.55) | HSD17B10LMNASMN1; SMN2ALDH1A1VCAM1 | |
| SCHEMBL4524457 | 0.85 | HSD17B10 (0.51) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2173166 | 0.84 | ALDH1A1 (0.58) | HSD17B10LMNAALDH1A1HTTPDE2A | |
| SCHEMBL13241715 | 0.84 | HSD17B10 (0.62) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL16293544 | 0.83 | KMT2A (0.49) | HSD17B10LMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL24723083 | 0.83 | ALDH1A1 (0.44) | LMNAALDH1A1KMT2AMEN1HTT | |
| SCHEMBL4532764 | 0.83 | ALDH1A1 (0.53) | LMNAALDH1A1HTTSLC6A4PDE2A | |
| SCHEMBL10417384 | 0.83 | L3MBTL1 (0.55) | LMNASMN1; SMN2ALDH1A1KDM4EKMT2A | |
| SCHEMBL4532457 | 0.83 | ALDH1A1 (0.55) | ALDH1A1KDM4EHTTPDE2APDE5A | |
| SCHEMBL5836477 | 0.82 | SLC6A4 (0.66) | HSD17B10ALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-06-13 | — | — | US | disclosed |
| EP-4313989-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117377673-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| EP-4238967-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2023-09-06 | — | — | EP | disclosed |
| US-20220363695-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2022-11-17 | — | — | US | disclosed |
| US-RE47451-E1 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO. LTD. (KR) | 2019-06-25 | — | — | US | disclosed |
| US-9156852-B2 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO., LTD (KR) | 2015-10-13 | — | — | US | disclosed |
| US-20140371219-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM. CO., LTD (KR) | 2014-12-18 | — | — | US | disclosed |
| EP-2797927-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013100632-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| CN-1738798-A | Indole derivatives as somatostatin agonists or antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-22 | — | — | CN | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371219-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | TK1, DTYMK, MAP4K2 | HSD17B10 3325/4885LMNA 3794/4885SMN1; SMN2 2262/4885 |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | HSD17B10 2328/4885LMNA 4241/4885SMN1; SMN2 4110/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | HSD17B10 4746/4885LMNA 1025/4885SMN1; SMN2 4036/4885 |
| US-20220363695-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HSD17B10 603/4885LMNA 3355/4885SMN1; SMN2 3277/4885 |
| US-12466841-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, HIPK3 | HSD17B10 1284/4885LMNA 3513/4885SMN1; SMN2 3266/4885 |
| US-12071442-B2 | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists | PDXK, HIPK1, PGK1 | HSD17B10 860/4885LMNA 3624/4885SMN1; SMN2 3520/4885 |
| US-20240190895-A1 | SUBSTITUTED PYRROLO[3,4-c]PYRIDINES AS HPK1 ANTAGONISTS | PDXK, HIPK1, HIPK3 | HSD17B10 1284/4885LMNA 3513/4885SMN1; SMN2 3266/4885 |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | AHR, ARNT, NOTUM | HSD17B10 790/4885LMNA 1651/4885SMN1; SMN2 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.